Form 4: Travere Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Jula Inrig, EVP, Head of R&D & CMO of Travere Therapeutics, Inc., sold 44,674 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 32,395 Common Stock at $8.93 ($289,287) on September 15, 2026; holds 145,165 after (Direct).
- Open-market sale: disposed of 25,390 Common Stock at $62.02 ($1,574,604) on September 15, 2026; holds 119,775 after (Direct).
- Open-market sale: disposed of 17,284 Common Stock at $62.62 ($1,082,397) on September 15, 2026; holds 102,491 after (Direct).
- Open-market sale: disposed of 1,600 Common Stock at $63.69 ($101,896) on September 15, 2026; holds 100,891 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $65.31 ($26,124) on September 15, 2026; holds 100,491 after (Direct).
- Option exercise/conversion: disposed of 32,395 Employee stock option (right to buy) on September 15, 2026; holds 43,605 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,785,021 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jula Inrig — Officer (EVP, Head of R&D & CMO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 32,395 | $9 | $289.3K | 145,165 |
| 2026-09-15 | Open-market sale | Common Stock | 25,390 | $62 | $1.6M | 119,775 |
| 2026-09-15 | Open-market sale | Common Stock | 17,284 | $63 | $1.1M | 102,491 |
| 2026-09-15 | Open-market sale | Common Stock | 1,600 | $64 | $101.9K | 100,891 |
| 2026-09-15 | Open-market sale | Common Stock | 400 | $65 | $26.1K | 100,491 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 32,395 | — | — | 43,605 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (32,395 shares) |
| 2026-09-15 | Open-market sale (25,390 shares) |
| 2026-09-15 | Open-market sale (17,284 shares) |
| 2026-09-15 | Open-market sale (1,600 shares) |
| 2026-09-15 | Open-market sale (400 shares) |
| 2026-09-15 | Option exercise/conversion (32,395 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Jula Inrig
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.